In a filing, Tyra Biosciences Inc revealed its Officer Daniel Bensen acquired Company’s shares for reported $2.0 million on Nov 18 ’25. In the deal valued at $16.05 per share,124,589 shares were bought.
Then, Bensen Daniel sold 110,228 shares, generating $1,765,489 in total proceeds. Upon selling the shares at $16.02, the Chief Operating Officer now owns 316,642 shares.
Before that, Bensen Daniel sold 20,072 shares. Tyra Biosciences Inc shares valued at $324,798 were divested by the Chief Operating Officer at a price of $16.18 per share. As a result of the transaction, Bensen Daniel now holds 296,570 shares, worth roughly $4.76 million.
Raymond James initiated its Tyra Biosciences Inc [TYRA] rating to a Strong buy in a research note published on September 03, 2025; the price target was $35. UBS began covering TYRA with “Buy” recommendation on January 07, 2025. BofA Securities revised its rating on October 18, 2024. It rated TYRA as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TYRA
On Tuesday, Tyra Biosciences Inc [NASDAQ:TYRA] saw its stock jump 0.88% to $16.04. Over the last five days, the stock has gained 6.01%. Tyra Biosciences Inc shares have fallen nearly -1.84% since the year began. Nevertheless, the stocks have risen 15.40% over the past one year. While a 52-week high of $17.27 was reached on 01/15/25, a 52-week low of $6.42 was recorded on 04/09/25.
Levels Of Support And Resistance For TYRA Stock
The 24-hour chart illustrates a support level at 15.17, which if violated will result in even more drops to 14.30. On the upside, there is a resistance level at 16.58. A further resistance level may holdings at 17.12.
How much short interest is there in Tyra Biosciences Inc?
A steep rise in short interest was recorded in Tyra Biosciences Inc stocks on 2025-10-31, dropping by -1.21 million shares to a total of 4.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 5.92 million shares. There was a decline of -25.69%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 15, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $33 price target.
